SCHEMBL6337277

SCHEMBL6337277

CCOC(=O)c1cc2c(OC)cc3c(c2n1Cc1ccccc1)CCCC3

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.52
PLA2G2A P14555 9/20 0.49
MAPT P10636 3/20 0.47
TSHR P16473 2/20 0.47
ALDH1A1 P00352 2/20 0.47
POLB P06746 1/20 0.47
ATM Q13315 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
NOD2 Q9HC29 1/20 0.46
NOD1 Q9Y239 1/20 0.46
F10 P00742 2/20 0.44
KDM4E B2RXH2 2/20 0.42
LMNA P02545 2/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
FABP4 P15090 2/20 0.42
GAA P10253 1/20 0.41
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6333044 0.90 PLA2G2A (0.49) KMT2APLA2G2AMAPTALDH1A1POLB
SCHEMBL6338332 0.89 PLA2G2A (0.51) KMT2APLA2G2AMAPTF10LMNA
SCHEMBL6338299 0.88 PLA2G2A (0.49) PLA2G2AFABP4
SCHEMBL6333151 0.86 PLA2G2A (0.50) PLA2G2AFABP4
SCHEMBL6333036 0.85 PLA2G2A (0.49) PLA2G2AFABP4
SCHEMBL6338323 0.82 PLA2G2A (0.48) PLA2G2AMAPTALDH1A1LMNAFABP4
SCHEMBL5160134 0.81 KMT2A (0.55) KMT2APLA2G2AMAPTTSHRALDH1A1
SCHEMBL6335034 0.80 PLA2G2A (0.48) PLA2G2AFABP4
SCHEMBL6337283 0.80 PLA2G2A (0.48) PLA2G2AMAPTTSHRALDH1A1LMNA
SCHEMBL6339378 0.79 PLA2G2A (0.46) PLA2G2AFABP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6974831-B2 sPLA2 inhibitors ELI LILLY AND COMPANY (US) 2005-12-13 US disclosed
US-20040077704-A1 Novel spla2 inhibitors BEIGHT DOUGLAS WADE (US) 2004-04-22 US disclosed
EP-1349834-A2 CYCLOALKYFUSED [G]-INDOLE COMPOUNDS AS SPLA2-INHIBITORS IN THE TREATMENT OF INFLAMMATORY DISEASES ELI LILLY AND COMPANY (US) 2003-10-08 EP disclosed
WO-2002050030-A2 CYCLOALKYLFUSED [G]-INDOLE COMPOUNDS AS SPLA2-INHIBITORS IN THE TREATMENT OF INFLAMMATORY DISEASES ELI LILLY AND COMPANY (US) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077704-A1 Novel spla2 inhibitors PLAAT2, PLA2G12A, PLA2G4A KMT2A 2924/4885PLA2G2A 19/4885MAPT 4806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.